Abstract 1447
Background
Pim-1 is an oncogene and has been proved to play pivotal role in proliferation, apoptosis and angiogenesis. Thyroid cancer represents the most common malignancy in the endocrine system and displays a marked increase in the incidence in recent years. Papillary thyroid cancer (PTC) is among the most frequent thyroid malignancies and accounts for more than 85%. Therefore, it is worthwhile to discuss the function of Pim-1 in the development and progression of PTC.
Methods
Gene set enrichment analysis (GSEA) of Pim-1 in the PTC was performed on the TCGA databases. 177 PTC paraffin blocks were selected to make the tissue microarrays and the levels of Pim-1 protein was investigated by immunohistochemistry. Meanwhile, one of the Pim-1 kinase inhibitor, SGI-1776, was used to evaluate the function of Pim-1 on the PTC cell BCPAP and TPC-1. CCK-8 and colony formation assay was carried out to measure the cell proliferation. Apoptosis rate and migration capacity were determined by flow cytometry and wound-healing methods respectively.
Results
GSEA results revealed that Pim-1 expression was significantly associated with the immune system of PTC. IHC result showed that Pim-1 was overexpressed in the PTC tissues compared with normal adjacent tissues. Meanwhile, Pim-1 had a significant relationship with the T-stage, lymph node involvement, capsule invasion and gender. Female patients and patients with higher T-stage, positive lymph node involvement, positive capsule invasion have a higher Pim-1 level. After SGI-1776 treatment, Pim-1 expressions were obviously downregulated in both BCPAP and TPC-1. Decreased Pim-1 led to the proliferation depression, apoptosis rate elevation and the migration capacity reduction in both cell lines.
Conclusions
Taken together, our current data showed the important role of Pim-1 in the tumorigenesis of PTC. High Pim-1 level linked to immune status and aggressive malignant behavior of PTC. It was also suggested that PIM-1 kinase might be a novel molecular biomarker of PTC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Zhejiang Province Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract